What Gilead Sciences Canada does

Gilead Sciences Canada is the wholly-owned Canadian subsidiary of Gilead Sciences, Inc., a publicly-traded biopharmaceutical company listed on NASDAQ under the ticker GILD. The Canadian entity, established in 2006 and headquartered in the Greater Toronto Area (Mississauga/Toronto), commercializes a portfolio of innovative prescription therapies across three core therapeutic areas: Virology (including HIV treatment and prevention, and curative therapies for hepatitis C), Oncology, and Inflammation. The parent company has been operating for more than 35 years with over 17,000 employees globally, and the Canadian operations function as a regional market entity within that enterprise.

The business operates a traditional pharmaceutical go-to-market model: Gilead Sciences Canada generates revenue through one-time prescription product sales, distributing via enterprise field sales to hospitals, clinics, pharmacies, and healthcare provider networks across Canada. Customer-facing activities are organized around healthcare professional communications, disease awareness campaigns, and structured community grants programs spanning HIV, Oncology and Hematology, and Liver disease. The company maintains a Canadian Leadership Team and engages external agency partners (e.g., Ogilvy Health) for creative pharmaceutical marketing, evidenced by a 2026 Cannes Lions Pharma Lions Bronze award.

Pricing is not publicly disclosed and is managed through Canadian healthcare system channels — public formularies, private insurance, and government drug programs. As a regional subsidiary of a large-cap US biopharma, Gilead Sciences Canada benefits from the parent's R&D pipeline, regulatory authorizations, and global commercial infrastructure, while operating within Health Canada's regulatory framework for prescription medicines serving Canadian patients with serious and life-threatening diseases.

Name

Gilead Sciences Canada

Legal name

Gilead Sciences, Inc.

Website

https://gilead.ca

Company type

Public

Founded year

1987

Operating status

Operating

Headcount range

251–500 employees

Short description

Gilead Sciences Canada is the wholly-owned Canadian subsidiary of Gilead Sciences, Inc., commercializing prescription therapies in Virology, Oncology, and Inflammation to Canadian patients through hospitals, pharmacies, and healthcare provider networks.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• HIV antiviral therapies
• Hepatitis C treatments
• Oncology therapeutics
• Biopharmaceutical medicines
• Inflammatory disease drugs

Headquarters

HQ city

Mississauga

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Gilead Sciences generates revenue through the sale of prescription pharmaceutical products, including treatments for HIV, hepatitis C, and other serious diseases. The company develops and commercializes innovative medicines globally.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Gilead Sciences Canada is the Canadian subsidiary of Gilead Sciences, Inc., a biopharmaceutical company that develops, manufactures, and commercializes prescription medicines in three core therapeutic areas: Virology (including HIV treatment and prevention and a cure for hepatitis C), Oncology, and Inflammation. The Canadian entity distributes these therapies through healthcare providers, hospitals, and pharmacies across Canada.

Product overview

Gilead Sciences Canada is a biopharmaceutical company focused on discovering and delivering transformative therapies for public health challenges. The company operates across three core therapeutic areas: Virology (including HIV treatment and prevention, and hepatitis C), Oncology, and Inflammation. Gilead's portfolio includes HIV treatments and prevention therapies, hepatitis C cures, and investigational therapies for other serious diseases. The company delivers its medicines through community grants programs spanning HIV, Oncology and Hematology, and Liver disease communities, connecting patients with access to care. The company employs more than 17,000 people globally and has been operating for over 35 years.

Differentiator

Problem solved

Functional benefit

Products and services

• HIV Treatments and Prevention Therapies Prescription pharmaceutical therapies for the treatment and prevention of HIV, developed over 35+ years of innovation; sold to healthcare providers and dispensed through pharmacies and hospitals in Canada.
• Hepatitis C Cure Therapies Prescription curative therapies for hepatitis C, representing a transformative advance in liver disease treatment; distributed through Canadian healthcare providers, hospitals, and pharmacies.
• Oncology Therapies Prescription pharmaceutical therapies for patients impacted by oncological diseases; sold to healthcare providers, hospitals, and specialty oncology centers in Canada.
• Inflammation Therapies Prescription therapies for patients impacted by inflammatory diseases; sold through Canadian healthcare providers and pharmacies.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered minor and core.

• Jazz PharmaceuticalsminorOthers · 26 June 2026Gilead Sciences Canada and Jazz Pharmaceuticals both received Bronze awards at the 2026 Cannes Lions Pharma Lions category, recognizing their respective pharmaceutical creativity campaigns.
• Ogilvy HealthcoreGTM or Marketing PartnerOgilvy Health is the agency partner for Viatris that won a Gold Lion at Cannes Lions 2026. Gilead also participated in the same awards, suggesting agencies are key partners in pharmaceutical marketing campaigns.

Scale indicators3 records

Recent moves3 records

Expansion highlights4 records

Direct peers

• Pfizer Canada: Canadian subsidiary of Pfizer Inc., a global biopharmaceutical company. Directly comparable as a major pharma manufacturer/distributor operating across multiple therapeutic areas (oncology, vaccines, inflammation, internal medicine) with enterprise sales into Canadian healthcare providers, hospitals, and pharmacies.
• Novartis Pharmaceuticals Canada: Canadian subsidiary of Novartis AG, a global biopharmaceutical company. Comparable therapeutic area overlap (oncology, inflammation, virology-adjacent) and comparable enterprise sales motion into Canadian healthcare providers.
• AstraZeneca Canada: Canadian subsidiary of AstraZeneca PLC, a major biopharmaceutical company. Comparable across oncology and specialty therapeutics with overlapping enterprise sales motion and similar regulatory/reimbursement exposure in Canada.
• ViiV Healthcare: Global specialist HIV company majority-owned by GSK with Pfizer and Shionogi as shareholders. The most direct competitor in Gilead's flagship virology franchise, competing head-to-head in HIV treatment and prevention with enterprise sales into the same HCP segments.
• Merck Canada: Canadian arm of Merck & Co. (MSD), a major biopharmaceutical company. Closely comparable in scale, therapeutic breadth (oncology, vaccines, virology), and enterprise go-to-market motion into Canadian healthcare provider networks.
• Roche Canada: Canadian operations of F. Hoffmann-La Roche, a global biopharmaceutical leader. Comparable across virology, oncology, and inflammation, with similar enterprise sales motion and specialty-pharma distribution model in Canada.
• Johnson & Johnson Innovative Medicine Canada (Janssen): Canadian pharmaceutical arm of J&J's Innovative Medicine division. Direct peer across virology, oncology, and immunology/inflammation, with comparable enterprise sales infrastructure and specialty-pharma portfolio strategy.
• AbbVie Canada: Canadian subsidiary of AbbVie Inc., a global biopharmaceutical firm. Highly comparable given overlapping therapeutic focus on virology (HIV via partnerships), immunology/inflammation, and oncology, with similar specialty-pharma enterprise sales motion in Canada.
• Bristol-Myers Squibb Canada: Canadian subsidiary of Bristol-Myers Squibb, a major biopharmaceutical company. Comparable in oncology and immunology focus, with overlapping virology heritage and similar enterprise sales motion into Canadian hospitals and specialty providers.

Broad incumbents

• GSK Canada: Canadian subsidiary of GSK plc, a global biopharmaceutical incumbent. Comparable as a broad-line pharmaceutical company with virology (HIV via ViiV), oncology, and inflammation exposure, though operating across a much wider portfolio than Gilead's focused three therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gilead Sciences Canada